journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/28442146/research-letter-evaluating-the-future-pathological-n-descriptors-for-lung-cancer-staging-in-a-uk-population
#1
LETTER
Tim Edwards, Haval Balata, Philip Foden, Philip Crosbie, Richard Booton, Matthew Evison
No abstract text is available yet for this article.
April 15, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28438350/microrna-505-modulates-cancer-proliferation-and-migration-in-human-non-small-cell-lung-cancer-through-inverse-regulation-of-fzd4
#2
Hong Li, Tian Yang, Qian Ning, Dong Shang, Yan Yao, Zhongmin Sun
OBJECTIVES: The current study is to evaluate the functional role of microRNA-505 (miR-505) in human non-small cell lung cancer (NSCLC). METHODS: Quantitative RT-PCR was performed to examine miR-505 expression in tumors of NSCLC patients and NSCLC cell lines. Lentiviruses of miR-505 mimics and miR-505 inhibitor were used to upregulate or downregulate miR-505 in NSCLC cell lines, A549 and H810 cells. Their effects on NSCLC in vitro growth, migration and in vivo growth were evaluated by proliferation, migration and tumorigenicity assays, respectively...
March 31, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28365051/optimal-front-line-alk-anaplastic-lymphoma-kinase-directed-therapy
#3
EDITORIAL
Shirish M Gadgeel
No abstract text is available yet for this article.
March 20, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28342657/targeting-bap1-a-new-paradigm-for-mesothelioma
#4
EDITORIAL
L M Schunselaar, W Zwart, P Baas
New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary...
March 18, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28343730/targeted-therapy-in-small-cell-lung-cancer-a-new-era
#5
EDITORIAL
Enrica Capelletto, Annapaola Mariniello, Silvia Novello
No abstract text is available yet for this article.
March 12, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28262265/an-interesting-observation-from-our-experiences-with-circulating-tumour-cells
#6
LETTER
Kok H Lim, Yong W Chua, Tony K H Lim, Angela M Takano
No abstract text is available yet for this article.
February 28, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28216065/preliminary-evaluation-of-a-telephone-based-smoking-cessation-intervention-in-the-lung-cancer-screening-setting-a-randomized-clinical-trial
#7
Kathryn L Taylor, Charlotte J Hagerman, George Luta, Paula G Bellini, Cassandra Stanton, David B Abrams, Jenna A Kramer, Eric Anderson, Shawn Regis, Andrea McKee, Brady McKee, Ray Niaura, Harry Harper, Michael Ramsaier
Incorporating effective smoking cessation interventions into lung cancer screening (LCS) programs will be essential to realizing the full benefit of screening. We conducted a pilot randomized trial to determine the feasibility and efficacy of a telephone-counseling (TC) smoking cessation intervention vs. usual care (UC) in the LCS setting. In collaboration with 3 geographically diverse LCS programs, we enrolled current smokers (61.5% participation rate) who were: registered to undergo LCS, 50-77 years old, and had a 20+ pack-year smoking history...
February 14, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28189265/how-should-ret-positive-nsclc-be-treated
#8
EDITORIAL
Egbert F Smit
No abstract text is available yet for this article.
February 6, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27492578/o-6-methylguanine-dna-methyltransferase-mgmt-a-drugable-target-in-lung-cancer
#9
Birgitta I Hiddinga, Patrick Pauwels, Annelies Janssens, Jan P van Meerbeeck
This manuscript addresses the role of O(6)-methylguanine-DNA methyltransferase (MGMT) as a biomarker in the oncogenesis of cancer and the opportunity of turning this gene into a drugable target in neuroendocrine tumours of the lung. Studies in brain tumours conclude that MGMT promoter methylation is considered a strong predictive factor for a favourable outcome for treatment with temozolomide, e.g. alkylating agent. We conducted a systematic review of MGMT in non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and other pulmonary neuroendocrine tumours (NETs) to evaluate whether MGMT is a prognostic and/or predictive factor to select patients with lung cancer who can benefit from treatment with temozolomide...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27372520/usp7-inhibitors-downregulating-ccdc6-sensitize-lung-neuroendocrine-cancer-cells-to-parp-inhibitor-drugs
#10
Umberto Malapelle, Francesco Morra, Gennaro Ilardi, Roberta Visconti, Francesco Merolla, Aniello Cerrato, Virginia Napolitano, Roberto Monaco, Gianluca Guggino, Guglielmo Monaco, Stefania Staibano, Giancarlo Troncone, Angela Celetti
OBJECTIVES: CCDC6 gene product is a tumor-suppressor pro-apoptotic protein, substrate of ATM, involved in DNA damage response and repair. Altered levels of CCDC6 expression are dependent on post-translational modifications, being the de-ubiquitinating enzyme USP7 responsible of the fine tuning of the CCDC6 stability. Thus, our aim was to investigate CCDC6 and USP7 expression levels in Lung-Neuroendocrine Tumors (L-NETs) to verify if they correlate and may be exploited as novel predictive therapeutic markers...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27372519/microrna-106a-targets-autophagy-and-enhances-sensitivity-of-lung-cancer-cells-to-src-inhibitors
#11
Sacha I Rothschild, Oliver Gautschi, Jasmin Batliner, Mathias Gugger, Martin F Fey, Mario P Tschan
OBJECTIVES: Src tyrosine kinase inhibitors (TKIs) significantly inhibit cell migration and invasion in lung cancer cell lines with minor cytotoxic effects. In clinical trials, however, they show modest activity in combination with chemotherapeutic agents. Possible resistance mechanisms include the induction of cytoprotective autophagy upon Src inhibition. Autophagy is a cellular recycling process that allows cell survival in response to a variety of stress stimuli including responses to various treatments...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27346245/precision-medicine-in-age-specific-non-small-cell-lung-cancer-patients-integrating-biomolecular-results-into-clinical-practice-a-new-approach-to-improve-personalized-translational-research
#12
Tiziana Vavalà, Valentina Monica, Marco Lo Iacono, Teresa Mele, Simone Busso, Luisella Righi, Mauro Papotti, Giorgio Vittorio Scagliotti, Silvia Novello
OBJECTIVES: Non-small-cell-lung-cancer (NSCLC) in young adults (≤45 years-old) accounts for a very small proportion, as this disease usually occurs in people at older age. The youthful NSCLC may constitute an entity with different clinical-pathologic characteristics, having predominance of adenocarcinoma histology and affecting mostly non-smoker subjects. However, without specific guidelines, it is currently considered, both clinically and biologically, as the same disease of the older counterpart, although differences have been documented...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27344275/integration-of-multiple-omic-biomarkers-a-precision-medicine-strategy-for-lung-cancer
#13
Ana I Robles, Curtis C Harris
More than half of all new lung cancer diagnoses are made in patients with locally advanced or metastatic disease, at which point therapeutic options are scarce. It is anticipated, however, that the widespread use of Low-Dose Computed Tomography (LDCT) screening, will lead to a greater proportion of lung cancers being diagnosed at an early, operable, stage. Still, the overall rate of recurrence for surgically treated Stage I lung cancer patients is up to 30% within 5 years of diagnosis. Thus, the identification and clinical application of biomarkers of early stage lung cancer are a pressing medical need...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27339469/possible-applications-of-circulating-tumor-cells-in-patients-with-non-small-cell-lung-cancer
#14
Alfredo Tartarone, Elisabetta Rossi, Rosa Lerose, Giuseppina Mambella, Giuseppe Calderone, Rita Zamarchi, Michele Aieta
Recent experiences indicate that, as already reported for other types of cancer, circulating tumor cells (CTCs) may play a role also in non small cell lung cancer (NSCLC) for diagnosis, therapy monitoring and prognostic purposes. CTCs evaluation could be particularly relevant in this clinical setting not only for the objective difficulty in obtaining tumor tissue, but also because of the lack of reliable tumor markers. In the current review, we will focus on the possible applications of CTCs in NSCLC patients...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27319335/personalizing-nsclc-therapy-by-characterizing-tumors-using-tki-pet-and-immuno-pet
#15
I Bahce, M Yaqub, E F Smit, A A Lammertsma, G A M S van Dongen, N H Hendrikse
Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27319334/cigb-300-an-anti-ck2-peptide-inhibits-angiogenesis-tumor-cell-invasion-and-metastasis-in-lung-cancer-models
#16
Fernando Benavent Acero, Carla S Capobianco, Juan Garona, Stéfano M Cirigliano, Yasser Perera, Alejandro J Urtreger, Silvio E Perea, Daniel F Alonso, Hernan G Farina
OBJECTIVES: Casein kinase 2 (CK2) is overexpressed in several types of cancer. It has more than 300 substrates mainly involved in DNA reparation and replication, chromatin remodeling and cellular growth. In recent years CK2 became an interesting target for anticancer drug development. CIGB-300 is a peptidic inhibitor of CK2 activity, designed to bind to the phospho-acceptor domain of CK2 substrates, impairing the correct phosphorylation by the enzyme. The aim of this work was to explore the antitumor effects of this inhibitor in preclinical lung cancer models...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27316470/cost-effectiveness-of-precision-medicine-in-the-fourth-line-treatment-of-metastatic-lung-adenocarcinoma-an-early-decision-analytic-model-of-multiplex-targeted-sequencing
#17
Brett Doble, Thomas John, David Thomas, Andrew Fellowes, Stephen Fox, Paula Lorgelly
OBJECTIVES: To identify parameters that drive the cost-effectiveness of precision medicine by comparing the use of multiplex targeted sequencing (MTS) to select targeted therapy based on tumour genomic profiles to either no further testing with chemotherapy or no further testing with best supportive care in the fourth-line treatment of metastatic lung adenocarcinoma. METHODS: A combined decision tree and Markov model to compare costs, life-years, and quality-adjusted life-years over a ten-year time horizon from an Australian healthcare payer perspective...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27312601/circulating-epigenetic-biomarkers-in-lung-malignancies-from-early-diagnosis-to-therapy
#18
Marco Tomasetti, Monica Amati, Jiri Neuzil, Lory Santarelli
Lung cancer (LC) and malignant mesothelioma (MM) are malignancies linked to environmental/occupational exposure, which are increasing in incidence. Despite advances in chemotherapy, radiation therapy and surgical management of LC and MM, the median survival remains less than 12 months. Early detection represents one of the most promising approaches to reducing the growing cancer burden by increasing chemotherapy treatment efficiency. At present, early diagnosis is rather difficult and depends on invasive sampling of pleural fluid or tissue...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27180141/circulating-cell-free-nucleic-acids-and-platelets-as-a-liquid-biopsy-in-the-provision-of-personalized-therapy-for-lung-cancer-patients
#19
L Sorber, K Zwaenepoel, V Deschoolmeester, P E Y Van Schil, J Van Meerbeeck, F Lardon, C Rolfo, P Pauwels
Lung cancer is the predominant cause of cancer-related mortality in the world. The majority of patients present with locally advanced or metastatic non-small-cell lung cancer (NSCLC). Treatment for NSCLC is evolving from the use of cytotoxic chemotherapy to personalized treatment based on molecular alterations. Unfortunately, the quality of the available tumor biopsy and/or cytology material is not always adequate to perform the necessary molecular testing, which has prompted the search for alternatives. This review examines the use of circulating cell-free nucleic acids (cfNA), consisting of both circulating cell-free (tumoral) DNA (cfDNA-ctDNA) and RNA (cfRNA), as a liquid biopsy in lung cancer...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27168021/precision-immunotherapy-dynamics-in-the-cellular-profile-of-pleural-effusions-in-malignant-mesothelioma-patients
#20
Lysanne A Lievense, Koen Bezemer, Robin Cornelissen, Margaretha E H Kaijen-Lambers, Joost P J J Hegmans, Joachim G J V Aerts
OBJECTIVES: Clinical studies have proven the potential of immunotherapy in malignancies. To increase efficacy, a prerequisite is that treatment is tailored, so precision immune-oncology is the logical next step. In order to tailor treatment, characterization of the patient's tumor environment is key. Pleural effusion (PE) often accompanies malignant pleural mesothelioma (MPM) and is an important part of the MPM environment. Furthermore, the composition of PE is used as surrogate for the tumor...
May 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"